Literature DB >> 12166044

Use of pharmacoeconomic data in making hospital formulary decisions.

Folakemi T Odedina1, Johanna Sullivan, Rowena Nash, C Denise Clemmons.   

Abstract

The use of pharmacoeconomic data in hospital formulary decisions was explored. Data were collected from pharmacist members of pharmacy and therapeutics (P&T) committees in 204 Florida hospitals. Participants were asked, via a cross-sectional telephone survey, to rate 10 factors used in making formulary decisions from 1 (most important) to 10 (least important). Participants were also asked about the usual sources of pharmacoeconomic data used by the P&T committee, the types of pharmacoeconomic analyses and humanistic outcome measures that have been used by the P&T committee to make formulary decisions, and the availability of someone with pharmacoeconomic skills to assist with the formulary decision-making. The average time spent collecting data was 19 minutes. Data were analyzed using descriptive statistics and correlation analysis. Eighty-six percent of the participants indicated that pharmacoeconomic data were used all the time or very often when formulary decisions were made, with only 6% stating that these data were rarely or never used. Pharmacoeconomic data were rated by 63% of participants to be very important in formulary decisions. The usual sources of pharmacoeconomic data listed by participants are inhouse data (75%), published literature (57%), and pharmaceutical industry studies (13%). Participants rated drug efficacy, toxicity, and side effects as the most important and avoiding use of home infusions as the least important factors in making hospital formulary decisions. About 70% of the hospitals had someone with pharmacoeconomic skills on staff, while 4% reported consulting with an external pharmacoeconomics expert. Most P&T committees in Florida hospitals relied on pharmacoeconomic data to assist them in making formulary decisions.

Entities:  

Mesh:

Year:  2002        PMID: 12166044     DOI: 10.1093/ajhp/59.15.1441

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  8 in total

1.  A qualitative approach to the use of economic data in the selection of medicines for hospital formularies: a French survey.

Authors:  Hans-Martin Späth; Marie Charavel; Magali Morelle; Marie-Odile Carrere
Journal:  Pharm World Sci       Date:  2003-12

Review 2.  Economic evaluations of healthcare programmes and decision making: the influence of economic evaluations on different healthcare decision-making levels.

Authors:  Marieke E van Velden; Johan L Severens; Annoesjka Novak
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  Health professionals: how do they assess new medicines?

Authors:  Rebecca Cheng; Kirsty Cook; Sarah Dowman; Rebecca Lawn; Jemma Leary; Taryn Quinn; Kim Schroder; Nicola Smith; June Tordoff
Journal:  Pharm World Sci       Date:  2005-06

4.  The role of pharmacoeconomics in formulary decision making in different hospitals in Riyadh, Saudi Arabia.

Authors:  Mohammed S Alsultan
Journal:  Saudi Pharm J       Date:  2010-11-04       Impact factor: 4.330

Review 5.  Literature review on the structure and operation of Pharmacy and Therapeutics Committees.

Authors:  Esther Durán-García; Bernardo Santos-Ramos; Francesc Puigventos-Latorre; Ana Ortega
Journal:  Int J Clin Pharm       Date:  2011-03-18

6.  Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.

Authors:  Ken LaPensee; Thomas Lodise
Journal:  Am Health Drug Benefits       Date:  2018-12

7.  A Comparative Analysis of Public Hospital Pharmacy Systems in Norway and Pakistan: A Pilot Implementation of the American Society of Health-System Pharmacists' (ASHP) Guidelines.

Authors:  Bilal Hasan Hashmi; Adnan Kisa
Journal:  Int J Environ Res Public Health       Date:  2022-06-27       Impact factor: 4.614

8.  The role of evidence in the decision-making process of selecting essential medicines in developing countries: the case of Tanzania.

Authors:  Amani Thomas Mori; Eliangiringa Amos Kaale; Frida Ngalesoni; Ole Frithjof Norheim; Bjarne Robberstad
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.